EUVIMEDOpdag EUVIMED
Open access

Glycolytic Enzymes as Vaccines Against Schistosomiasis: Testing Schistosoma mansoni Phosphoglycerate Mutase in Mice

David B Pirovich, Akram A Da'dara, Patrick J Skelly iD

Journal of Parasitology · 2024-03-11 · 110 (2) · 96-105

DOI: 10.1645/23-7 ↗

At a glance

Journal article in Journal of Parasitology, published on 2024-03-11. Written by David B Pirovich and 2 co-authors. Institution: Molecular Helminthology Laboratory, Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, Nor…. Major MEDLINE topics: Schistosomiasis mansoni, Schistosomiasis, Vaccines. Cited 2 times so far (Crossref); 56 references. The full text is freely available in PubMed Central. Funded by: NIAID NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Schistosomiasis is a globally burdensome parasitic disease caused by flatworms (blood flukes) in the genus Schistosoma. The current standard treatment for schistosomiasis is the drug praziquantel, but there is an urgent need to advance novel interventions such as vaccines. Several glycolytic enzymes have been evaluated as vaccine targets for schistosomiasis, and data from these studies are reviewed here. Although these parasites are canonically considered to be intracellular, proteomic analysis has revealed that many schistosome glycolytic enzymes are additionally found at the host-interactive surface. We have recently found that the intravascular stage of Schistosoma mansoni (Sm) expresses the glycolytic enzyme phosphoglycerate mutase (PGM) on the tegumental surface. Live parasites display PGM activity, and suppression of PGM gene expression by RNA interference diminishes surface enzyme activity. Recombinant SmPGM (rSmPGM) can cleave its glycolytic substrate, 3-phosphoglycerate and can both bind to plasminogen and promote its conversion to an active form (plasmin) in vitro, suggesting a moonlighting role for this enzyme in regulating thrombosis in vivo. We found that antibodies in sera from chronically infected mice recognize rSmPGM. We also tested the protective efficacy of rSmPGM as a vaccine in the murine model. Although immunization generates high titers of anti-SmPGM antibodies (against both recombinant and native SmPGM), no significant differences in worm numbers were found between vaccinated and control animals.

Subjects

MeSH terms (MEDLINE)

Schistosomiasis mansoniSchistosomiasisVaccinesAnimalsMiceSchistosoma mansoniPhosphoglycerate MutaseProteomicsAntigens, HelminthAntibodies, Helminth

Author keywords

Schistosoma mansoniEnzymeGlycolysisPhosphoglycerate mutaseSchistosomeVaccinationVaccine

Substances

Phosphoglycerate MutaseVaccinesAntigens, HelminthAntibodies, Helminth

Authors and institutions

  • Molecular Helminthology Laboratory, Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts 01536.

ORCID profiles: Patrick J Skelly

Funding

  • NIAID NIH HHS

Cite

APA

Pirovich, D. B., Da'dara, A. A., & Skelly, P. J. (2024). Glycolytic Enzymes as Vaccines Against Schistosomiasis: Testing Schistosoma mansoni Phosphoglycerate Mutase in Mice. Journal of Parasitology, 110(2), 96-105. https://doi.org/10.1645/23-7

Vancouver

Pirovich DB, Da'dara AA, Skelly PJ. Glycolytic Enzymes as Vaccines Against Schistosomiasis: Testing Schistosoma mansoni Phosphoglycerate Mutase in Mice. Journal of Parasitology. 2024;110(2):96-105. doi:10.1645/23-7

BibTeX
@article{Pirovich2024,
  author = {Pirovich, David B and Da'dara, Akram A and Skelly, Patrick J},
  title = {Glycolytic Enzymes as Vaccines Against Schistosomiasis: Testing Schistosoma mansoni Phosphoglycerate Mutase in Mice},
  journal = {Journal of Parasitology},
  year = {2024},
  volume = {110},
  number = {2},
  pages = {96--105},
  doi = {10.1645/23-7}
}
Start for free →